Utilizing Medicare claims data for real-time drug safety evaluations: Is it feasible?

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 7, 2011, Pages 684-688

  Hartzema, Abraham G ^a   Racoosin, Judith A ^b   Macurdy, Thomas E ^c,d   Gibbs, Jonathan M ^d   Kelman, Jeffrey A ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Acumen LLC   (United States)

^e Ctr for Medicare and Medicaid Serv   (United States)

Author keywords

Active drug safety surveillance; Administrative claims data; Claims adjudication; Medicare; Real time safety evaluation

Indexed keywords

ACUTE HEART INFARCTION; DATA BASE; DRUG SAFETY; HEALTH SERVICE; HOSPITAL; HOSPITAL PATIENT; HUMAN; MEDICAID; MEDICAL INFORMATION SYSTEM; MEDICARE; NOTE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL;

DATABASES, FACTUAL; FEASIBILITY STUDIES; HUMANS; INSURANCE CLAIM REPORTING; INSURANCE CLAIM REVIEW; MEDICARE; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; UNITED STATES;

EID: 79959720663     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2143     Document Type: Note

References (4)

1. FDA. MedWatch: the FDA safety information and adverse event reporting program. FDA/MedWatch, Rockville, April 2010. [accessed 21 April 2010].
2. FDA. Postmarketing clinical trials. FDA/CBER, Rockville; June 2009. [accessed 21 April 2010].
3. McAdams M, Staffa J, Dal Pan G, Estimating the Extent of Reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2008; 17: 229-239.
4. CMS. Medicare Claims Processing Manual. CMS, Baltimore, February 2010. [21 April 2010].